The use of deferiprone and methods to treat and/or prevent Friedreich ataxia resulting from intracellular mishandling of iron

摘要

570730 Disclosed is the use of deferiprone, or a physiologically acceptable salt thereof, in the manufacture of a medicament to preferentially reduce or render inactive the toxic iron stores in the subcellular compartments of the brain; preferentially reduce or render inactive the toxic iron stores in the mitochondria for the prevention of mitochondrial iron-induced damage; preferentially reduce or render inactive the toxic iron stores in the mitochondria for the treatment of mitochondrial iron-induced damage or treatment of Friedreich ataxia resulting from mitochondrial iron-induced damage.